Ozmosi

@OzmosiHealth

BioPharma/Biotech Intel. Daily $XBI $XPH Market Movers Database: http://Pryzm.ozmosi.com Clinical trial tools: http://BEAM-CI.com https://buff.ly/3s78UT3

World & Business

Roche’s divarasib reportedly yielded almost six months longer survival than rivals in lung cancer study

Bloomberg reports the late-stage comparison involved previously treated patients whose non-small cell lung cancer had spread.

7 Sources, 3h ago, first seen 3h ago

Featured in

Roche’s divarasib reportedly yielded almost six months longer survival than rivals in lung cancer study

Featured in

Roche’s divarasib reportedly yielded almost six months longer survival than rivals in lung cancer study